Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 11, 2016 08:00 ET | Source: MyoKardia, Inc.

MyoKardia Announces Exploratory Digital Health Substudy as Part of PIONEER-HCM Trial of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients

Trial to Assess Potential Effects of MYK-461 Treatment on Arterial Pulse Wave Morphology as Measured by Investigational Optical Biosensor Wristband SOUTH SAN FRANCISCO, Calif., Nov. 11, 2016 ...
November 07, 2016 08:00 ET | Source: MyoKardia, Inc.

MyoKardia Reports Progress on Clinical Programs and Third Quarter 2016 Financial Results

Dosing in Phase 2 PIONEER-HCM trial of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Under Way; Pathway to Registration...
November 04, 2016 08:00 ET | Source: MyoKardia, Inc.

MyoKardia Announces Presentations at American Heart Association Scientific Sessions 2016

Clinical Data from Phase 1 SAD Trials of MYK-461 in Hypertrophic Cardiomyopathy Patients and Healthy Volunteers New Animal Model Research Advances Understanding of HCM Pathophysiology SOUTH SAN...
November 02, 2016 08:00 ET | Source: MyoKardia, Inc.

MyoKardia Announces Dosing of First Patient in Phase 2 PIONEER-HCM Study of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy

Pilot Study Designed to Enable Progression to Larger Phase 2 Trial to Finalize Dosing and Endpoints Prior to Single Pivotal Study Trial Will Assess 12-week...
October 31, 2016 08:00 ET | Source: MyoKardia, Inc.

MyoKardia to Present at Two Upcoming Investor Conferences in November

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the...
October 03, 2016 16:30 ET | Source: MyoKardia, Inc.

MyoKardia Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
September 27, 2016 18:47 ET | Source: MyoKardia, Inc.

MyoKardia Announces Pricing of Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
September 26, 2016 16:48 ET | Source: MyoKardia, Inc.

MyoKardia Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
September 21, 2016 07:00 ET | Source: MyoKardia, Inc.

MyoKardia Outlines Path to Registration for MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients and Provides Pipeline and Research Updates at Inaugural R&D Day

Phase 2 PIONEER-HCM Pilot Study of MYK-461 Under Way with Topline Data Expected in Second Half of 2017 Mortality-Based Efficacy Endpoints Not Required for Registration of MYK-461...
September 14, 2016 08:45 ET | Source: MyoKardia, Inc.

MyoKardia to Host R&D Day on September 21

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment...